RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:86872

T-cell large granular lymphocyte leukemia

low confidenceDisorder

Also known as: Proliferation of large granular lymphocytes · T-LGL · T-cell LGL leukemia

Publications

2,237

Trials

54

Interventional, condition-specific

Researchers

1,255

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

T-cell large granular lymphocyte leukemia (T-cell LGL leukemia) is a lymphoproliferative malignancy that arises from the mature T-cell (CD3+) lineage.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (19)

LGLL · T gamma lymphoproliferative disorder · T-LGL leukaemia · T-LGL leukemia · T-cell LGL leukaemia · T-cell large gran. lymph. leuk. · T-cell large granular lymphocytic leukaemia · T-cell large granular lymphocytic leukemia · T-gamma lymphoproliferative disorder · Tgamma large granular lymphocyte leukaemia · Tgamma large granular lymphocyte leukemia · large cell granular lymphogenous leukaemia · large cell granular lymphogenous leukemia · large cell granular lymphoid leukaemia · large cell granular lymphoid leukemia · large granular lymphocytic leukemia · large granular lymphocytosis · leukemia, large granular LYMPHOCYTIC, malignant · proliferation of large granular lymphocytes

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    2,237 matched papers (1,281 in last 10 years) Source

  3. Phenotype characterisedNot found

    No HPO disease–phenotype associations via Monarch for these Mondo IDs

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    54 matched on ClinicalTrials.gov (7 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

15

Drugs / clinical candidates · MONDO_0019469

CTD chemicals (MyDisease.info)

1 associated chemical · 35 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • Sulfasalazine · therapeutic

Pathways: ErbB signaling pathway; Chemokine signaling pathway; Jak-STAT signaling pathway; Th1 and Th2 cell differentiation; Th17 cell differentiation; Prolactin signaling pathway; AGE-RAGE signaling pathway in diabetic complications; Hepatitis B

MyDisease.info · MONDO:0019469

Literature

Is anyone studying this?

2,237

2,237 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

2,237 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

1,281 in the last 10 years · low confidence

Phrase hits: 2,237 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,255

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Gorodetskiy V6 papers · 2024

    Department of Intensive Methods of Therapy, V. A. Nasonova Research Institute of Rheumatology Moscow, Russia.

    Papers in Europe PMC
  2. 02
    Gurnari C6 papers · 2024

    Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.

    Papers in Europe PMC
  3. 03
    Shi M6 papers · 2026

    Mayo Clinic, Rochester, MN.

    Papers in Europe PMC
  4. 04
    Sudarikov A6 papers · 2024

    Laboratory of Molecular Hematology, National Research Center for Hematology Moscow, Russia.

    Papers in Europe PMC
  5. 05
    Kim HK5 papers · 2025

    Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. lukekhk@snu.ac.kr.

    Papers in Europe PMC
  6. 06
    Li Y5 papers · 2026

    State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, 288 Nanjing Road, Heping District, Tianjin, 300020, China.

    Papers in Europe PMC
  7. 07
    Maciejewski JP5 papers · 2024

    Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.

    Papers in Europe PMC
  8. 08
    Park S5 papers · 2025

    Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

    Papers in Europe PMC
  9. 09
    Ryzhikova N5 papers · 2024

    Laboratory of Molecular Hematology, National Research Center for Hematology Moscow, Russia.

    Papers in Europe PMC
  10. 10
    Sidorova Y5 papers · 2024

    Laboratory of Molecular Hematology, National Research Center for Hematology Moscow, Russia.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

54

interventional trials for this specific condition

54 interventional trials matched this specific condition name; 7 currently recruiting in our sample.

Data as of 11 September 2026

54 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 97.3th percentile).

low confidence · 97.3th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

54 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for T-cell large granular lymphocyte leukemia — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"T-cell large granular lymphocyte leukemia" OR "Proliferation of large granular lymphocytes" OR "Proliferation of the large granular lymphocytes" OR "T-LGL" OR "T-cell LGL leukemia" OR "T gamma lymphoproliferative disorder" OR "T-LGL leukaemia" OR "T-LGL leukemia" OR "T-cell LGL leukaemia" OR "T-cell large gran. lymph. leuk." OR "T-cell large granular lymphocytic leukaemia" OR "T-cell large granular lymphocytic leukemia" OR "T-gamma lymphoproliferative disorder" OR "Tgamma large granular lymphocyte leukaemia" OR "Tgamma large granular lymphocyte leukemia" OR "large cell granular lymphogenous leukaemia" OR "large cell granular lymphogenous leukemia" OR "large cell granular lymphoid leukaemia" OR "large cell granular lymphoid leukemia" OR "large granular lymphocytic leukemia" OR "large granular lymphocytosis" OR "leukemia, large granular LYMPHOCYTIC, malignant"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"T-cell large granular lymphocyte leukemia" OR "Proliferation of large granular lymphocytes" OR "Proliferation of the large granular lymphocytes" OR "T-LGL" OR "T-cell LGL leukemia" OR "T gamma lymphoproliferative disorder" OR "T-LGL leukaemia" OR "T-LGL leukemia" OR "T-cell LGL leukaemia" OR "T-cell large gran. lymph. leuk." OR "T-cell large granular lymphocytic leukaemia" OR "T-cell large granular lymphocytic leukemia" OR "T-gamma lymphoproliferative disorder" OR "Tgamma large granular lymphocyte leukaemia" OR "Tgamma large granular lymphocyte leukemia" OR "large cell granular lymphogenous leukaemia" OR "large cell granular lymphogenous leukemia" OR "large cell granular lymphoid leukaemia" OR "large cell granular lymphoid leukemia" OR "large granular lymphocytic leukemia" OR "large granular lymphocytosis" OR "leukemia, large granular LYMPHOCYTIC, malignant"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 54 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: LGLL

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (2237) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T03:15:12.182Z